Development and validation of novel proliferation-related gene signature for MSS colorectal cancer prognosis DOI Creative Commons
Sen Wang, Zhiyu Yu, Peng Xu

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 18, 2024

Abstract Colorectal cancer (CRC) is classified into microsatellite instability (MSI) and stabilized (MSS) based on the differences in DNA repair mechanisms. In recent years, many studies have proved that some emerging therapeutic approaches good effects MSI as a subtype but are ineffective for MSS subtype. This paper aims to start with molecular mechanism of try find characteristic target genes We used bioinformatics techniques machine learning GTF2IRD1. The gene GTF2IRD1 highly expressed MSS-type CRC stable MSI. Subsequently, we verified its expression function relevant experiments. demonstrated can promote proliferation colorectal correlate poor prognosis patients, which may provide potential clinical treatment cancer.

Language: Английский

Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis DOI Open Access
Yiran Zhang,

Hanyang Guan,

Shijin Liu

et al.

Published: Jan. 21, 2025

An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges.In this phase II trial, received Gamma Knife SBRT combined Tislelizumab. P Biomarker analysis was performed pre- post-treatment. From November 2022 to July 2024, 13 20 achieved PR, 6 SD. mPFS 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse included nausea (65%), anemia (55%), fatigue (45%). For who had not responded first second-line therapies, combo tislelizumab showed high reasonable safety. Significant post-radiotherapy improvements in tumor’s microenvironment. These results imply that pMMR/MSS/MSI-L were unresponsive chemotherapy, provides a safe powerful later-line treatment alternative.

Language: Английский

Citations

0
Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis DOI Open Access
Yiran Zhang,

Hanyang Guan,

Shijin Liu

et al.

Published: Jan. 21, 2025

An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges.In this phase II trial, received Gamma Knife SBRT combined Tislelizumab. P Biomarker analysis was performed pre- post-treatment. From November 2022 to July 2024, 13 20 achieved PR, 6 SD. mPFS 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse included nausea (65%), anemia (55%), fatigue (45%). For who had not responded first second-line therapies, combo tislelizumab showed high reasonable safety. Significant post-radiotherapy improvements in tumor’s microenvironment. These results imply that pMMR/MSS/MSI-L were unresponsive chemotherapy, provides a safe powerful later-line treatment alternative.

Language: Английский

Citations

0
The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis DOI
Danning Zhang, Tianyu Chen

Journal of Gastrointestinal Cancer, Journal Year: 2025, Volume and Issue: 56(1)

Published: Jan. 29, 2025

Language: Английский

Citations

0
High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT) DOI Creative Commons

Yuxuan Ding,

Yong Feng,

Yangfan Ye

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 6, 2025

Microsatellite stable (MSS) colorectal cancer with liver metastases (CLRM) responds poorly to immunotherapy, and various approaches break immune tolerance have been tried. Radiotherapy in combination checkpoint inhibitors is one of promising therapies, the choice radiotherapy immunotherapy modalities also a hot issue. Here, we report on Phase I trial treating nine patients MSS CLRM using high low dose (ICIs). The primary endpoint was safety tolerability this treatment modality. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS) overall (OS). study results showed that at three levels-single doses 6Gy (n=3), 8Gy 10Gy (n=3)-the most common treatment-related adverse events (TRAEs) were nausea, vomiting, fatigue, abnormal function. At first condition assessment, four observed disease (SD) patient achieved partial (PR). In exploratory analyses, tissue biopsies paired hematologic samples from M2 macrophage reduction. Plasma cytokines IL-10, IL-17, INF-α increased after both drugs. summary, clinical demonstrating immunogenic activity combined ICIs (CRLMs). therapy stimulated altered tumour microenvironment, warranting further exploration future.

Language: Английский

Citations

0
Exploring the Role of Cellular Interactions in the Colorectal Cancer Microenvironment DOI Creative Commons
Jiadai Tang, Lixin Chen, Xin Shen

et al.

Journal of Immunology Research, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 1, 2025

Colorectal cancer (CRC) stands as one of the tumors with globally high incidence and mortality rates. In recent years, researchers have extensively explored role tumor immune microenvironment (TME) in CRC, highlighting crucial influence cell populations driving progression shaping therapeutic outcomes. The TME encompasses an array cellular noncellular constituents, spanning cells, myeloid tumor-associated fibroblasts, among others. However, composition within is highly dynamic, evolving throughout different stages progression. These shifts subpopulation proportions lead to a gradual transition response, shifting from early antitumor growth late-stage environment that supports survival. Therefore, it further investigate understand complex interactions various TME. this review, we explore key components varying origins, subpopulations shared elements CRC TME, examining their interconnections critical considerations for developing personalized precise immunotherapy strategies.

Language: Английский

Citations

0
Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies DOI Creative Commons

Marwa Abdel Hamid,

Lorenz M. Pammer,

Silvia Oberparleiter

et al.

npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)

Published: April 22, 2025

Despite advances in metastatic colorectal cancer (mCRC) treatment, long-term survival remains poor, particularly right-sided (RCRC), which has a worse prognosis compared to left-sided CRC (LCRC). This disparity is driven by the complex biological diversity of these malignancies. RCRC and LCRC differ not only clinical presentation outcomes but also their underlying molecular genetic profiles. article offers detailed literature review focusing on distinctions between LCRC. We explore key differences across embryology, anatomy, pathology, omics, tumor microenvironment (TME), providing insights into how factors contribute therapeutic responses. Furthermore, we examine implications differences, considering whether conventional classification right- forms should be refined. Recent findings suggest that this binary may overlook critical complexities. Therefore, propose future approaches integrate better guide personalized treatments, especially anti-EGFR therapies, improve patient outcomes.

Language: Английский

Citations

0
Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis DOI Creative Commons
Yiran Zhang,

Hanyang Guan,

Shijin Liu

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 13, 2024

Abstract An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges.In this phase II trial, received Gamma Knife SBRT combined Tislelizumab. P Biomarker analysis was performed pre- post-treatment. From November 2022 to July 2024, 13 20 achieved PR, 6 SD. mPFS 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse included nausea (65%), anemia (55%), fatigue (45%). For who had not responded first second-line therapies, combo tislelizumab showed high reasonable safety. Significant post-radiotherapy improvements in tumor’s microenvironment. These results imply that pMMR/MSS/MSI-L were unresponsive chemotherapy, provides a safe powerful later-line treatment alternative. Statement significance This study offers option for fail chemotherapy. And discover contributed potentially converting suppressive “cold” immune into an activated “hot” conducive immunotherapy CRC.

Language: Английский

Citations

0
Development and validation of novel proliferation-related gene signature for MSS colorectal cancer prognosis DOI Creative Commons
Sen Wang, Zhiyu Yu, Peng Xu

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 18, 2024

Abstract Colorectal cancer (CRC) is classified into microsatellite instability (MSI) and stabilized (MSS) based on the differences in DNA repair mechanisms. In recent years, many studies have proved that some emerging therapeutic approaches good effects MSI as a subtype but are ineffective for MSS subtype. This paper aims to start with molecular mechanism of try find characteristic target genes We used bioinformatics techniques machine learning GTF2IRD1. The gene GTF2IRD1 highly expressed MSS-type CRC stable MSI. Subsequently, we verified its expression function relevant experiments. demonstrated can promote proliferation colorectal correlate poor prognosis patients, which may provide potential clinical treatment cancer.

Language: Английский

Citations

0